西藏药业(600211.SH)：依姆多(中国市场)获得药品补充申请批件

智通财经网10-14

智通财经APP讯，西藏药业(600211.SH)发布公告，公司全资子公司西藏诺迪康科技发展有限公司于近日收到国家药品监督管理局颁发的《药品补充申请批准通知书》，药品通用名称为单硝酸异山梨酯缓释片，商品名称为依姆多。依姆多功能主治：冠心病的长期治疗、预防血管痉挛型和混合型心绞痛，也适用于心肌梗死后的治疗及慢性心衰的长期治疗。本次取得国家药品监督管理局颁发的依姆多(中国市场)药品补充申请批准通知书，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2475803332?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-14 16:24","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2475803332","market":"sg","top_or_hot":-1,"title":"西藏药业(600211.SH)：依姆多(中国市场)获得药品补充申请批件","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，西藏药业(600211.SH)发布公告，公司全资子公司西藏诺迪康科技发展有限公司于近日收到国家药品监督管理局颁发的《药品补充申请批准通知书》，药品通用名称为单硝酸异山梨酯缓释片，商品名称为依姆多。依姆多功能主治：冠心病的长期治疗、预防血管痉挛型和混合型心绞痛，也适用于心肌梗死后的治疗及慢性心衰的长期治疗。本次取得国家药品监督管理局颁发的依姆多(中国市场)药品补充申请批准通知书，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1193360.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>西藏药业(600211.SH)：依姆多(中国市场)获得药品补充申请批件</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n西藏药业(600211.SH)：依姆多(中国市场)获得药品补充申请批件\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-14 16:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1193360.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，西藏药业(600211.SH)发布公告，公司全资子公司西藏诺迪康科技发展有限公司于近日收到国家药品监督管理局颁发的《药品补充申请批准通知书》，药品通用名称为单硝酸异山梨酯缓释片，商品名称为依姆多。依姆多功能主治：冠心病的长期治疗、预防血管痉挛型和混合型心绞痛，也适用于心肌梗死后的治疗及慢性心衰的长期治疗。本次取得国家药品监督管理局颁发的依姆多(中国市场)药品补充申请批准通知书，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1193360.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"YINN","symbol_name":"三倍做多富时中国ETF-Direxion","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1193360.html","article_id":"2475803332","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475803332","pubTimestamp":1728894245,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，西藏药业 发布公告，公司全资子公司西藏诺迪康科技发展有限公司于近日收到国家药品监督管理局颁发的《药品补充申请批准通知书》，药品通用名称为单硝酸异山梨酯缓释片，商品名称为依姆多。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600211":"西藏药业","YINN":"三倍做多富时中国ETF-Direxion","BK0239":"医药制造","BK4585":"ETF&股票定投概念","BK0033":"西藏振兴","BK4588":"碎股"},"translate_title":"Tibet Pharmaceutical (600211. SH): Imdo (Chinese market) obtained approval for drug supplementary application","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600211":1,"YINN":1},"content_text":"智通财经APP讯，西藏药业(600211.SH)发布公告，公司全资子公司西藏诺迪康科技发展有限公司于近日收到国家药品监督管理局颁发的《药品补充申请批准通知书》，药品通用名称为单硝酸异山梨酯缓释片，商品名称为依姆多。依姆多功能主治：冠心病的长期治疗、预防血管痉挛型和混合型心绞痛，也适用于心肌梗死后的治疗及慢性心衰的长期治疗。本次取得国家药品监督管理局颁发的依姆多(中国市场)药品补充申请批准通知书，表明依姆多(中国市场)生产转换工作已完成，标志着继依姆多(中国市场)完成上市许可持有人变更后，依姆多重大资产重组后续事项取得重大进展，同时新增了依姆多的生产场地和原料药供应商，有利于保障依姆多的稳定供应。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475803332"}